Respironics Inc. announced the FDA clearance of the I-neb Adaptive Aerosol Delivery (AAD) System for the aerosolization of liquid medication approved for use with the I-neb AAD System.
The device is cleared for use by the patient in the home care, nursing home, sub-acute institution or hospital environment.
The system continually monitors and automatically adapts to an individual patient's breathing pattern to deliver a precise medication dose during the patient's inhalation phase. It is Respironics' third generation AAD system and is smaller, quieter and more portable than earlier product generations. The I-neb device also provides audible and visual feedback to patients informing them that the treatment is complete.
The first application of I-neb in the U.S. will be at the end of the year through CoTherix, Inc., a South San Francisco-based biopharmaceutical company.